Natural Alternatives International, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6388423021
USD
3.45
-0.1 (-2.82%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Natural Alternatives International, Inc. stock-summary
stock-summary
Natural Alternatives International, Inc.
Pharmaceuticals & Biotechnology
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. The Company operates through three segments: private-label contract manufacturing, patent and trademark licensing, and branded products. The private-label contract manufacturing segment primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other healthcare products. The patent and trademark licensing segment primarily includes direct raw material sales and royalty income from its license and supply agreements associated with the sale and use of beta-alanine under its CarnosSyn trade name. The branded products segment relates to the marketing and distribution of branded nutritional supplements and consists primarily of the products sold under its Pathway to Healing product line.
Company Coordinates stock-summary
Company Details
1535 Faraday Ave , CARLSBAD CA : 92008-7319
stock-summary
Tel: 1 619 7447340
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (13.6%)

Foreign Institutions

Held by 6 Foreign Institutions (0.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Mark LeDoux
Chairman of the Board of Directors, Chief Executive Officer
Mr. Joe Davis
Independent Director
Mr. Alan Dunn
Independent Director
Mr. Alan Lane
Independent Director
Mr. Lee Weldon
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Mar 2025)
Net Profit:
-2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 32 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.03

stock-summary
Return on Equity

-10.35%

stock-summary
Price to Book

0.42